Light-absorbing pharmaceutical packaging
The multilaminate secondary packaging for pharmaceuticals, using SBS cardboard with aluminum laminate and black matte ink, effectively blocks visible and NIR light, addressing the inadequacies of conventional packaging and improving photostability of optically active drugs.
Patent Information
- Application Number
- JP2024526802
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-19
- Filing Date
- 2022-09-23
- Publication Date
- 2024-11-08
AI Technical Summary
Conventional secondary packaging for pharmaceutical products, primarily made of solid bleached sulfate (SBS) cardboard, is inadequate in blocking visible and near-infrared (NIR) light, which can degrade optically active pharmaceuticals such as NIR fluorescent contrast agents.
A multilaminate secondary packaging material comprising SBS cardboard with additional layers of aluminum laminate and black matte ink or MET-PET, configured to attenuate light by a factor of 4 or more, effectively blocking 99.99% or more of incident visible and NIR light.
The multilaminate packaging significantly enhances the photostability of optically active pharmaceuticals by reducing light exposure to a level equivalent to a 4-hour exposure in traditional packaging over a 5-year period, providing enhanced protection against degradation.
Smart Images

Figure 2024541290000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This patent application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 281,322, filed November 19, 2021, the contents of which are incorporated by reference as if fully set forth herein.
[0002] The present invention relates to secondary packaging for pharmaceutical products. [Background technology]
[0003] Pharmaceuticals are often supplied in primary packaging enclosed in secondary packaging, which typically includes glass pharmaceutical vials manufactured to ISO 8362-1 and available in a range of colours from clear to amber.
[0004] Most pharmaceuticals do not absorb visible or near infrared (NIR) light, and traditional standard secondary packaging is made of solid bleached board (SBB) or solid bleached sulfate (SBS). SBS is a virgin fiber grade paperboard (often called SBS cardboard). SBS blocks UV light well enough that it is perfectly suitable for secondary packaging of most pharmaceuticals. Thus, little attention has been paid to the visible and NIR wavelengths that can penetrate SBS cardboard. Light-absorbing optically active pharmaceuticals (such as, but not limited to, NIR fluorescent contrast agents for image-guided surgery) absorb energy in the spectral ranges of 400-650 nm (visible) and 650-850 nm (NIR) and are therefore susceptible to degradation when exposed to such wavelengths.
[0005] Thus, there is an urgent need for improved secondary packaging for optically active pharmaceutical ingredients. Summary of the Invention [Problem to be solved by the invention]
[0006] The present invention has been made to solve the problems in the conventional techniques described above. [Means for solving the problem]
[0007] SUMMARY OF THE DISCLOSURE Embodiments of the present invention relate to improved secondary packaging for light absorbing, i.e., light sensitive (eg, NIR light sensitive) pharmaceutical products.
[0008] A secondary pharmaceutical packaging having SBS cardboard and one or more additional layers of a multilaminate material configured to improve photostability for an optically active pharmaceutical in a vial held within the secondary pharmaceutical packaging by blocking incident visible and / or near infrared (NIR) light attenuated by at least 4 log factor in optical density, The multilaminate material may include SBS cardboard having a thickness range of 10-26 points or more and any of (i) aluminum laminate and black ink and / or black matte ink, (ii) MET-PET and black ink and / or black matte ink, (iii) aluminum laminate only, and (iv) MET-PET only.
[0009] The secondary packaging may be configured as a pharmaceutical carton capable of blocking greater than 99.99%, such as greater than 99.999%, or even greater than 99.99999% of incident visible and NIR light.
[0010] An embodiment of the present invention relates to a pharmaceutical packaging material comprising a cardboard having opposing first and second primary surfaces, the first primary surface defining an outer surface of the pharmaceutical packaging material. The cardboard has a thickness in the range of 10 to 26 points. The packaging material also includes a light scattering material applied to at least one of the first and second primary surfaces of the cardboard and a light absorbing material on the light scattering material, defining an inner and / or outer surface of the pharmaceutical packaging material.
[0011] The pharmaceutical packaging may be provided in combination with a vial containing a light absorbing pharmaceutical product and held within a carton.
[0012] The board may be a solid bleached sulfate (SBS) board.
[0013] Yet another aspect of the invention relates to a pharmaceutical package including a glass vial containing an optically active pharmaceutical agent and a carton holding the glass vial, the carton including a multi-laminate construction of cardboard and one or more additional layers configured to block incident visible and / or near infrared (NIR) light by attenuating the optical density by a factor of at least 4 log, thereby providing increased photostability to the optically active pharmaceutical agent in the vial over cardboard alone.
[0014] The light scattering and light absorbing materials may have a cumulative thickness of less than 10% (on average) of the thickness of the cardboard.
[0015] The pharmaceutical packaging material may be configured to block incident visible and / or near infrared (NIR) light by attenuating the optical density by 4 log or more.
[0016] The light scattering material may include an aluminum laminate directly laminated or directly adhered to the first and / or second primary surfaces of the cardboard.
[0017] The light absorbing material may include black ink applied to a light scattering material.
[0018] The light absorbing material may include and / or be provided by a black matte ink applied to a light scattering material.
[0019] The pharmaceutical packaging material may be provided as a carton.
[0020] The thickness of the cardboard may range from 10 to 26 points. One or more additional layers may be provided by either: (i) aluminum laminate and black or black matte ink, (ii) MET-PET and black or black matte ink, (iii) aluminum laminate alone, and (iv) MET-PET alone.
[0021] The cardboard may have an overall thickness range of 10 to 26 points and may define a white outer surface of the carton. One or more additional layers may include an aluminum laminate.
[0022] The board may be a solid bleached sulfate (SBS) board.
[0023] The pharmaceutical packaging may include a black ink that may be applied to an aluminum laminate to define the inner and / or outer surfaces of the carton.
[0024] The pharmaceutical packaging may include a black ink that may be applied to an aluminum laminate to define the inside surface of the carton.
[0025] The pharmaceutical packaging may include a black matte ink that may be applied to an aluminum laminate to define the inner and / or outer surfaces of the carton.
[0026] The pharmaceutical packaging may include a black matte ink that may be applied to an aluminum laminate to define the inside surface of the carton.
[0027] The carton's multi-laminate construction is configured to block greater than about 99.99% of incident visible and NIR light.
[0028] The multi-laminate construction of the carton may be configured to block greater than about 99.9999% of incident visible and NIR light.
[0029] It should be noted that aspects of the invention described with respect to one embodiment may be incorporated into other embodiments not specifically described. That is, all of the embodiments and / or all features of any embodiment may be combined in any manner and / or in any combination. Applicant reserves the right to modify any originally filed claims or to submit any new claims accordingly, including the right to amend any originally filed claim to depend on and / or incorporate any feature of any other claim not originally so claimed. The detailed description set forth below sets forth these and other objects and / or aspects of the invention in detail.
[0030] Other systems and / or methods according to embodiments of the invention will become apparent to one of ordinary skill in the art upon examination of the following figures and detailed description, and all such other systems, methods, and / or apparatus are intended to be encompassed herein, be within the scope of the invention, and be protected by the accompanying claims.
[0031] Other features of the present invention will be more readily understood from the following detailed description of illustrative embodiments of the invention, taken in conjunction with the accompanying drawings, in which: [Brief description of the drawings]
[0032] [Figure 1A] 1 is a graph showing the relationship between wavelength (nm) and transmittance (%) for three 500 ml glass vials: clear, protective color, and amber. [Figure 1B] 1 is a graph showing wavelength (nm) vs. transmittance (%), where curve C corresponds to clear (flint) glass, curve G corresponds to green glass, and curve A corresponds to amber (brown) glass, with the transmittance (%) representing "weak" and "good" protection at various wavelengths. [Diagram 2] 1 is a graph of wavelength (nm) versus optical density (OD) on a logarithmic scale illustrating the light transmission and spectral filtering of various secondary packaging materials according to embodiments of the present invention. [Diagram 3] A series of digital photographs in accordance with an embodiment of the invention, from left to right: a 2 logarithmic neutral density filter (ND2 filter) placed between the light source and the camera ("light source only"), 14pt virgin white SBS cardboard / paperboard, 14pt SBS cardboard and MET-PET, 10pt SBS cardboard and aluminum laminate; all images have a 50ms exposure time and the same brightness, contrast, and gamma settings. [Figure 4] FIG. 2 is a schematic diagram of a secondary packaging carton with vials and leaflets therein, and an exploded view of a multi-laminate structure of the packaging material, according to an embodiment of the present invention. [Diagram 5] FIG. 2 is an open-top view of a secondary packaging carton shown in a ready-to-store configuration according to an embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0033] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will now be described in more detail with reference to the accompanying drawings, in which embodiments of the present invention are shown. However, the present invention may be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
[0034] Like reference numbers refer to like elements throughout. In the drawings, certain line thicknesses, layers, components, elements, or features may be exaggerated for clarity. Dashed lines indicate optional features or operations, unless otherwise noted. One or more features illustrated and described with respect to one embodiment may be included in another embodiment even if not explicitly described or shown in another embodiment.
[0035] The terms used herein are for the purpose of describing particular embodiments only and are not intended to be limiting of the present invention. As used herein, the singular forms "a," "an," and "the" are intended to encompass the plural forms as well, unless the context clearly indicates otherwise. It is further understood that the terms "comprises" and / or "comprising," as used herein, specify the presence of stated features, integers, steps, operations, elements, and / or components, and do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof. As used herein, the term "and / or" encompasses any combination of one or more of the associated listed items. As used herein, phrases such as "between X and Y" and "between about X and Y" should be interpreted as including X and Y. As used herein, phrases such as "between about X and Y" mean "between about X and about Y." As used herein, phrases such as "from about X to Y" mean "from about X to about Y."
[0036] Unless otherwise defined, the meaning of all terms (including technical and scientific terms) used herein is the same as that commonly understood by those skilled in the art to which the present invention belongs. It is further understood that words, for example, words defined in commonly used dictionaries, should be interpreted as having a meaning consistent with the meaning of those words in the context of the present specification and the related art, and should not be interpreted as an idealized meaning or an overly formal meaning unless expressly defined as such in the present specification. Well-known functions or structures may not be described in detail for brevity and / or clarity.
[0037] It will be understood that when an element is referred to as being "adjacent," "attached," "connected," "coupled," "in contact," or the like, the element may be directly adjacent, connected, coupled, or in contact with the other element, or there may be intervening elements. In contrast, when an element is referred to as being "directly adjacent," "directly attached," "directly connected," "directly coupled," or "in direct contact" with another element, there are no intervening elements present. Additionally, as will be understood by those skilled in the art, when a structure or feature is referred to as being "adjacent" to another feature, the reference may include portions that overlap or underlie the adjacent feature.
[0038] Spatially relative terms such as "under," "below," "lower," "over," "upper," and the like may be used herein for ease of description when describing the relationship of one element or feature to another element or feature as depicted in the figures. It should be understood that the spatially relative terms are intended to encompass other orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures were inverted, an element described as being "under" or "beneath" another element or feature would be oriented "over" that other element or feature. Thus, for example, the term "under" may encompass both an orientation of "over" and "under." The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, terms such as "upwardly," "downwardly," "vertical," "horizontal," etc. are used herein for descriptive purposes only, unless otherwise specified.
[0039] In this specification, terms such as first, second, etc. may be used to describe various elements, components, regions, levels, and / or sections, but it is understood that these elements, components, regions, levels, and / or sections are not limited by these terms. These terms are used only to distinguish one element, component, region, level, or section from another region, level, or section. Thus, a first element, component, region, level, or section discussed below may be referred to as a second element, component, region, level, or section without departing from the teachings of the inventive concept. The order of operations (or steps) is not limited to the order shown in the claims or drawings unless another order is specifically indicated.
[0040] The term "about" means that the stated number or value can vary by ±20%.
[0041] The term "optically active pharmaceutical agent" refers to a pharmaceutical agent that is light absorbing and therefore photosensitive, such as visible dyes (e.g., methylene blue) and NIR photosensitive pharmaceutical agents, such as fluorescent pharmaceutical agents used in therapy and / or surgery (e.g., indocyanine green). Further examples of such pharmaceutical agents include, but are not limited to, pharmaceutical agents that are visible colors, such as green or blue, in dry powder, liquid, or tablet formulations.
[0042] The term "sterile" and its derivatives mean that the device or material in question meets or exceeds the requirements of medical guidelines regarding sterility, such that it will be substantially free of contamination (if not completely) for at least the specified shelf life, suitable for its intended medical use in humans or animals.
[0043] The term "aseptic" is used interchangeably with the word "sterile." In some embodiments, the aseptic processing or manufacturing of the vials and filling of the vials adheres to GMP (Good Manufacturing Practice) industry guidelines, such as those associated with Guidance for Industry--Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice, US Department of Health and Human Services Food and Drug Administration, September 2004.
[0044] Pharmaceutical glass vials manufactured to ISO 8362-1 are available in a range of colors from clear to amber. Intuitively, it would seem that a darker color, such as amber, would be better at blocking NIR light. In reality, amber vials are rather poor at blocking NIR light. As shown in Figures 1A and 1B, amber glass is quite effective at blocking light below 500 nm, especially UV light. However, literature reports that for NIR wavelengths, the light transmission ranges from 25% to 80%. See Carl Roth GMBH, Duran, Wheaton, and Kimble Glassware Tables and General Information (Figure 1A) and Glass wine bottles and UV light, WRAP Information Sheet, wrap.org.uk (Figure 1B).
[0045] In addition to the ineffectiveness of amber vials in blocking NIR light, regulatory agencies often disapprove of such vials because particulates are less visible during release testing. This is particularly important in Japan, which has the strictest particulate specifications of any country. This means that the primary packaging has a trade-off between blocking NIR light and being able to evaluate the final drug product for particulates. Amber vials offer little benefit in the former regard and significant risk in the latter regard.
[0046] Therefore, in response to a long felt, recognized and growing need, the present invention has invested significant time, effort and resources into developing secondary packaging that provides maximum blocking of visible and NIR light, and therefore protection of light absorbing and light sensitive pharmaceuticals.
[0047] In one example shown in Figure 4, a pharmaceutical product 200 is enclosed in a primary package 100, which is held within a secondary package 10. For the purposes of the secondary package 10, light has only two possible outcomes: absorption or scattering. There are various types of light scattering, but the two most relevant to pharmaceutical secondary packaging are multiple scattering events by opaque materials and reflection from mirror-like surfaces.
[0048] The most common material for pharmaceutical packaging is virgin white solid bleached sulfate (SBS) cardboard, 10-26 point (0.25-0.66 mm) thick. SBS cardboard is relatively opaque to the human eye, but is not very effective at attenuating light, especially NIR light. This is because the white exterior and brown interior absorb very little light, and the cardboard thickness does not allow for enough scattering events to prevent light from penetrating the carton. Interestingly, white SBS cardboard also fluoresces itself, with broadband fluorescence peaking in the blue, so UV-absorbed energy can be re-radiated into the package.
[0049] Using the test equipment and protocols described below under the heading "Experimental Design," the light blocking capabilities of various materials of approximately comparable thickness were quantified. As shown in Table 1, SBS cardboard (14 point) achieves an optical density (OD) attenuation of only 3.2 over the 400-900 nm spectral range. This allows for a huge photon flux to penetrate, given the constant exposure in a typical storage area such as a busy, well-lit pharmacy, and the total exposure is the integral of the total time the secondary packaging carton is on the shelf, which can be weeks or months. And, as seen in Figure 2, due to Rayleigh scattering, NIR light penetrates the secondary packaging material better and is less blocked than visible light.
[0050] The inventors have recognized / discovered that an improved secondary packaging for photosensitive pharmaceuticals is long-awaited, due to the relatively poor performance of SBS cardboard in terms of light blocking in general, and NIR light in particular. Despite the fact that photosensitive pharmaceuticals have been in use for over 60 years to date, these photosensitive pharmaceuticals are enclosed in secondary packaging made solely of SBS cardboard, which only attenuates approximately 99.9% of the visible and NIR light incident thereon. The inventors have recognized this deficiency and have recognized that an improved photostability for photosensitive pharmaceuticals is long-awaited. The inventors have recognized that an efficient and cost-effective way to achieve this goal is to improve the secondary packaging to achieve light scattering and light absorption.
[0051] The inventors investigated several materials. The first was SBS cardboard (14 point) coated with black matte ink, but this only resulted in 7 times greater attenuation than SBS cardboard alone. As known to those skilled in the art, the term "point" (abbreviated as "pt.") is used to describe the thickness of a sheet of paper, including corrugated packaging paper. Thickness is measured with a vernier caliper, with one point representing 1 / 1000 of an inch.
[0052] Next, SBS coated with a thin layer of metallized (aluminum) polyester (called MET-PET) was tested. Typical MET-PET films are 5-20 μm thick, or about 1-10% of the total thickness depending on the total thickness. MET-PET is a standard material in retail packaging, used for light blocking, and has surfaces that range from highly reflective to matte. A 14pt total thickness SBS coated with reflective MET-PET only further reduced light transmission by a factor of 8 compared to SBS cardboard coated with black matte ink (Table 1 and Figure 2). In contrast, a combination of SBS cardboard and MET-PET coated with an ultra-thin layer of black matte ink (typically 5-20 μm) in a 14pt total thickness further reduced light transmission, which may be suitable for some applications.
[0053] [Table 1]
[0054] Another paper technology, called aluminum laminate, was also evaluated as an alternative material, as shown in Figure 2 and Table 1. This is a very thin sheet of solid aluminum foil (typically 5-20 μm) laminated directly to one of the primary surfaces of SBS cardboard (SBS+aluminum laminate) to a total thickness of 10 pt. Although aluminum foil is thin and only a small fraction of the total thickness of the packaging material (e.g., 1-10% depending on the thickness of the aluminum and the total thickness), it was an unexpected surprise that it became a very effective light blocking material. In the case of SBS+aluminum laminate, no visible or NIR light was detected transmitted through the material (measurements were at the noise level of the spectrometer). In fact, SBS+aluminum laminate with black matte ink applied to a total thickness of 10 pt attenuated light 4 log times that of SBS cardboard alone (which corresponds to 10,000 times) (Table 1 and Figure 2). Figure 2 shows the light transmission and spectral filtering from 400 to 900 nm for the materials listed in Table 1.
[0055] Figure 3 shows that the penetration of NIR light is higher than visible light for all materials except SBS + aluminum laminate. The light of the point source is attenuated and blurred as it passes through the SBS cardboard, and is further attenuated by the addition of MET-PET. Complete light blocking is only achieved with the aluminum laminate. In the "light source only" image (left side), a 2 log neutral density filter (ND2 filter) was placed between the light source and the camera to prevent camera saturation. The exposure time (50 ms) and brightness, contrast, and gamma settings are the same for all images. The secondary packaging 10 with SBS cardboard and aluminum laminate can be configured to completely or nearly completely block NIR light (rightmost photo). As shown in Figures 4 and 5, the cardboard may be configured to define at least one primary surface, shown as the outer surface 10e of the carton 10c, and a black ink or black matte ink may form or define the inner surface 10i. The reverse configuration can also be used. In some embodiments, the inner and outer primary surfaces of the cardboard carton 10c may have black or black matte ink applied to one or more aluminum laminate layers or directly to the cardboard surface. FIG. 5 also shows a flap 112 with black or black matte ink applied to the inner surface 10i of the flap 112. The cardboard may be any suitable cardboard material and does not have to be SBS cardboard. For example, it may be Clay Coated News Back (CCNB), Folding Box Board (FBB), Natural Kraft (SUS), and Coated Unbleached Kraft (CUK), each of which by themselves have NIR light transmission issues.
[0056] FIG. 4 is a schematic diagram of a secondary package 10 comprising a rectangular carton 10c holding a primary package 100 enclosing a pharmaceutical product 200, which may be liquid. The primary package 100 may be provided as a sterile glass vial, the glass of which may be transparent. The glass vial 100v may be of any suitable size, for example in some embodiments ranging in size from 4 ml to 500 ml. Larger and smaller vials may also be used. The secondary package 10 may enclose a folded product insert (information) leaflet ("PIL") 120, which is typically in a folded configuration with a closed bottom and an open top to form an elongated open space 120, whereby the vial 100 may be placed into the open space 120s. As shown in FIG. 4, the carton 10c may be rectangular, with a height "h" greater than a width "w". In some particular embodiments, the carton 10c may be 70 mm high, and 35 mm wide and deep. However, cartons of other shapes and sizes may be used.
[0057] The secondary packaging 10 may include three layers 11, 12, 13 of three different materials. The three layers 11, 12, 13 may be three laminate layers. The first layer 11 may be provided by a cardboard 11c (optionally an SBS cardboard) and may define the majority of the thickness of the secondary packaging 10 (typically 90-99% of the total thickness). The thickness of the cardboard 11c may be in the range of 10-26 points. The total thickness of the package may be in the range of 10-26 points. The cardboard 11c may have opposing outer primary surfaces 11o and inner primary surfaces 11i. The outer primary surface 11o may define the outer surface 10e of the carton 10c (the outer surface 10e may optionally be a virgin white SBS outer surface).
[0058] The second layer 12 may be a photon scattering material and the third layer 13 may be a photon absorbing material. The second layer 12 and the third layer 13 may be the same or different thicknesses, provided that the overall thickness of the package is within the desired thickness range (typically 10-26 pts).
[0059] The secondary packaging 10 may have an inner surface 10i defined by a third layer 13. The third layer 13 may be composed of or may include a black matte (pigment) ink 13i, which comprises a photon absorbing material and may be printed, coated, rolled or sprayed onto a second layer 12 of a photon scattering material (e.g., MET-PET or aluminum laminate). The term "black matte" is well known to those skilled in the art and refers to a pigment / ink that is highly absorbent for all wavelengths of light (e.g., all photons) and does not cause surface reflection (scattering). The black matte layer may be applied in parts by applying a transparent matte finish after the black ink. In some embodiments, a black ink may be used instead of the black matte ink. In some embodiments, one or more layers of black ink may be used with one or more layers of a semi-transparent matte finish (e.g., varnish). The black ink and translucent matte finish, when used in combination, can define the interior or exterior surface, or both, of the packaging material 10 / carton 10c.
[0060] The second layer 12 is preferably provided by an aluminum laminate as described above, although in some embodiments the second layer 12 may be provided by MET-PET.
[0061] An example of aluminum foil that can be used for the aluminum laminate layer can be found at www.alfipa.com / products / aluminum-foil-metallized-pet-film / . MET-PET can be of comparable thickness, but has a much lower optical density because it is a mixture of plastic and metal. See www.jindalpoly.com / products / met-pet. Black ink can be applied at comparable thickness (5-20 μm), but typically depends on the number of "passes" made to create that layer. See www.zxprinter.com / support / ink-film-thickness.html. All three websites cited were accessed as of November 19, 2021, and are incorporated herein by reference as if set forth in their entirety herein.
[0062] Also, even if light does manage to get through a very small tear in the fold of the carton, the black matte pigment (ink) 13i applied (e.g., printed) on the aluminum laminate surface 12 can absorb such light leakage. The black matte ink is highly absorbent for all wavelengths of light and does not cause surface reflection (i.e., scattering). Thus, photons that hit the black matte surface are prevented from being reflected back toward the medicine or drug in the primary package 100 / vial 100v and are simultaneously absorbed (FIG. 4). Alternatively, black ink alone may be used if surface reflection is not considered a high risk. As shown in Table 1 and FIG. 2, SBS cardboard + aluminum laminate + black matte ink is almost as good as SBS cardboard + aluminum laminate without black matte ink / pigment in terms of light attenuation properties, but the presence of black matte ink on the inside surface of the carton provides maximum protection of the inside of the carton from reflected NIR light. Folded product insert leaflets (PILs) required by regulatory agencies to be included in cartons can provide additional light protection for vials, but PILs are often restricted to specific shapes and sizes, making them an unreliable method of light protection.
[0063] In particular, the secondary packaging 10 forming the pharmaceutical carton 10c can provide light blocking with a transmission of less than about 0.000048% (e.g., between about 0.000008% and 0.000006%). In some embodiments, the packaging material of the pharmaceutical carton 10c can block greater than 99.99%, greater than 99.999%, or greater than 99.99999% of incident visible and NIR light. To put this level of performance in perspective, a pharmaceutical product protected by the secondary packaging described herein would receive the same amount of energy when exposed to light for five years as a pharmaceutical product protected by a current conventional SBS carton would receive when exposed to the same light for just 4 hours and 28 minutes.
[0064] The present inventors have recognized a long-standing problem and identified a need for improved packaging of light-sensitive pharmaceuticals that has gone unnoticed in the field for over 60 years. The novel carton 10c can significantly improve the light protection of optically active pharmaceuticals that have traditionally been provided in standard SBS cardboard secondary packaging for over 60 years. With the increasing medical use of light absorbing dyes and fluorophores, this new secondary packaging can provide improved photostability over conventional secondary packaging, addressing a significant unsolved problem.
[0065] The invention is described in more detail in the following non-limiting Examples. Working Example
[0066] Experimental Design: A Cary 5000 scanning spectrometer was used to obtain the data shown in Table 1 and Figure 2. Monochromatic light with a cone angle of F / 7 was directed onto the sample using an aperture to reduce the effects of scattering.
[0067] Summary: With regard to primary packaging, amber vials offer little advantage over clear vials in attenuating NIR light and are significantly more difficult to test for particulate release than clear vials.
[0068] With regard to secondary packaging, the typical virgin white SBS cardboard used in the manufacture of pharmaceutical cartons is ineffective at blocking both visible and NIR light. The novel material of the present invention is comprised of a multi-laminate of light absorbing and scattering materials, which is capable of blocking light energy that can degrade NIR fluorescent contrast agents while still providing the clean white exterior surface expected of pharmaceutical cartons.
[0069] To put the results in perspective, a drug vial stored in a secondary packaging carton provided by an embodiment of the present invention receives the same amount of light energy when exposed to continuous light for five years as the same drug vial stored in a conventional SBS carton receives when exposed to light for just four hours and 28 minutes.
[0070] The above is illustrative of the embodiments of the present invention and should not be construed as being limited to those embodiments. Although only a few exemplary embodiments of the present invention have been described, those skilled in the art can easily understand that various modifications can be made in those exemplary embodiments without substantially departing from the novel teachings and advantages of the present invention. Therefore, all such modifications are intended to be included within the scope of the present invention as defined in the claims. The present invention is defined by the following claims, and equivalents of the claims are intended to be encompassed by the claims.
Claims
1. A pharmaceutical packaging material comprising: a cardboard including opposing first and second primary surfaces, the first primary surface defining an outer surface of the pharmaceutical packaging material, the cardboard having a thickness in the range of 10 to 26 points; a light scattering material applied to the first and / or second primary surfaces of the cardboard; a light absorbing material on the light scattering material; Pharmaceutical packaging materials including:
2. 2. The pharmaceutical package of claim 1, wherein said light scattering material and said light absorbing material have a cumulative thickness that is less than 10% (on average) of the thickness of said cardboard.
3. The pharmaceutical packaging material of claim 1, wherein the pharmaceutical packaging material blocks incident visible light and / or near infrared (NIR) light by attenuating the optical density by 4 log-fold or more.
4. 2. The pharmaceutical packaging material of claim 1, wherein the light scattering material is defined by an aluminum laminate directly laminated or directly adhered to the first and / or second primary surfaces of the cardboard.
5. The pharmaceutical packaging material of claim 1 , wherein the light absorbing material comprises a black ink applied to the light scattering material.
6. 10. The pharmaceutical packaging material of claim 1, wherein the light absorbing material comprises a black matte ink applied to the light scattering material.
7. The pharmaceutical packaging material of claim 1 , wherein the pharmaceutical packaging material is provided as a carton.
8. 10. The pharmaceutical packaging material of claim 1, wherein the paperboard comprises solid bleached sulfate (SBS) paperboard.
9. 8. The pharmaceutical package of claim 7 in combination with a vial containing a light absorbing pharmaceutical product held within said carton.
10. A glass vial containing an optically active pharmaceutical ingredient; a carton for holding the glass vials, the carton comprising a multi-laminate construction of cardboard and one or more additional layers configured to provide increased photostability for the optically active pharmaceutical agent in the vial over SBS cardboard alone by blocking incident visible and / or near infrared (NIR) light with an optical density attenuation of at least 4 log factor; Pharmaceutical packaging including:
11. 11. The pharmaceutical packaging of claim 10, wherein the cardboard has a thickness range of 10-26 points and the one or more additional layers are provided by any of: (i) aluminum laminate and black or black matte ink; (ii) MET-PET and black or black matte ink; (iii) aluminum laminate alone; and (iv) MET-PET alone.
12. 11. The pharmaceutical package of claim 10, wherein the board is SBS board having an overall thickness range of 10-26 point defining a white outer surface of the carton, and the one or more additional layers comprises an aluminum laminate.
13. 11. The pharmaceutical package of claim 10, wherein the one or more additional layers include an aluminum laminate, and the pharmaceutical package further comprises a black ink applied to the aluminum laminate.
14. The pharmaceutical package of claim 13 , wherein the black ink defines an interior surface of the carton.
15. 13. The pharmaceutical packaging of claim 12, further comprising a black matte ink applied to the aluminum laminate defining an inner and / or outer surface of the carton.
16. 11. The pharmaceutical packaging of claim 10, wherein the multi-laminate construction of the carton is configured to block greater than about 99.99% of incident visible and NIR light.
17. 11. The pharmaceutical packaging of claim 10, wherein the multi-laminate construction of the carton is configured to block greater than about 99.9999% of incident visible and NIR light.
Citation Information
Patent Citations
Cold -proof corrugated container board
CN206306552U
Packaging material for photosensitive material
JP1985151045A
Light-shielding paper
JP1997026648A
Packaging body for photographic sensitive material
JP2001142177A
Internal material for lithographic printing plate
JP2007245513A
